ORDER A TEST Log In Contact Us

Data-driven
precision medicine

Bringing the power of data and artificial intelligence to healthcare

With the power of AI, we now have the ability to

  • ACCELERATE

    the discovery of novel targets

  • PREDICT

    the effectiveness of treatments

  • IDENTIFY

    potentially life-saving clinical trials

  • DIAGNOSE

    multiple diseases earlier

WATCH OUR STORY

Explore Tempus

PROVIDERS

We can help physicians make more informed treatment decisions.

Learn More
LIFE SCIENCES

We can assist pharmaceutical and biotech companies with better drug development.

Learn More
PATIENTS

We can help patients find their own unique and optimal therapy options.

Learn More
OUR PLATFORM

We have built a proprietary Platform to make data accessible and deploy AI at scale.

Learn More

Our Science

Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.

View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing. A Pan-cancer Organoid Platform for Precision Medicine Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers. Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.

Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery

50%+ of all Academic Medical Centers in the US are connected to Tempus
40%+ of oncologists in the US connected to Tempus through sequencing, clinical trial matching, and research-enabled partnerships
2/3 of the top 20 pharma oncology companies partner with Tempus
140+ biopharma partnerships
5,500,000+ de-identified research records to power scientific discovery to improve patient outcomes
16,000+ patients were identified for potential enrollment into clinical trials in our network
60+ petabytes of data

Tempus Announces Agreement With the U.S. Department of Veterans Affairs National Precision Oncology Program

The VA’s National Precision Oncology Program is collaborating with Tempus to expand access to its portfolio of sequencing offerings to support physicians in delivering personalized care for their patients with cancer.

READ ARTICLE

Tempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease

The rECHOmmend study, published in Circulation, demonstrated a novel machine learning model that uses data from a 12-lead ECG to identify patients at high risk of undiagnosed SHD.

READ PRESS RELEASE

Tempus Founder & CEO Op-Ed “We need health data banks not unlike what we have for organ donors”

Eric Lefkofsky discusses how de-identified data can enable doctors and researchers to learn from the experience of today’s patients to help tomorrow’s.

READ PRESS RELEASE

This is data-driven precision medicine

This is the future of healthcare.

Contact Us ORDER A TEST